Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus.
about
Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.Assessment of in silico models for fraction of unbound drug in human liver microsomes.Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipineTime Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats.Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKDInhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevanceInterspecies pharmacokinetics and in vitro metabolism of SQ109.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions.The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.In vitro approaches to investigate mechanism-based inactivation of CYP enzymes.Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.The conduct of drug metabolism studies considered good practice (II): in vitro experimentsCurrent industrial practices in assessing CYP450 enzyme induction: preclinical and clinicalInhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenolsThe effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.Assessment of reactive metabolites in drug-induced liver injury.In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability.Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.Transporter effects on cell permeability in drug delivery.Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.The use of wireless laptop computers for computer-assisted learning in pharmacokineticsGenotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions.Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin.Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function.Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.Metabolism of the hepatotoxic compound sophoraflavanone G in rat liver microsomes.In vitro inhibitory effects of Wen-pi-tang-Hab-Wu-ling-san on human cytochrome P450 isoforms.
P2860
Q31814815-8B958F4E-9FB1-44F1-B672-24BF6E448651Q33541186-62CDB2FB-491E-4FC1-9A88-C8D031441EDEQ34180470-055C9802-8519-4D20-BC21-29D9276261B0Q34419498-992C841C-B791-4544-ACAE-8DD9F5021D6AQ34455184-E21B9FF1-94B9-4100-A18B-4186848293A2Q34785485-9BC61BCD-EE38-495C-AF45-49B502CE4068Q35100649-5C228A73-5677-42F9-B173-6F972CCC44E6Q35129048-9335F910-8F26-4F71-B526-DCF59EA3C987Q35579544-3CDC0B30-71BE-431F-9E6C-FF6DB1C3B7AEQ35827865-22AA9AD7-EB37-46E8-8E8D-F4B0B360DB81Q36387998-8EBC81DB-019D-4FC6-BD2C-A40585B67F11Q36662853-F3D75DE6-BA51-4B7F-A73A-3200E16F3D7EQ36835799-A467ED04-07A0-4043-A744-CB78B12EE6CAQ36985079-1D97FC4D-F01D-492D-9D2E-567AD845D18EQ37065422-4A031344-DB64-4F2D-A819-646C003F8078Q37237446-3B7E6911-225F-4328-A300-27EA2C0C7553Q37704691-A9A835E5-0A62-4E30-B761-0B0B132C413CQ37770251-EB4B8564-4A1B-4832-97EB-3C78C7764521Q37771144-AFF467BA-DE4C-4857-A348-A05F9BDB28ABQ37964578-61CB65E9-A9A3-4049-928C-009EACA28C26Q38107523-B916EF2D-0588-4AC9-946D-0BE107396E0DQ38346846-3CB1266D-5826-4C68-945C-EBAAB672B967Q38905979-13AD3F2D-B582-445D-A3F2-308EAF2C123FQ38962616-4FE27851-E2BB-4884-92AE-F37B166525E4Q39130137-3906D0D9-270F-4EA2-8E75-902EEE1CE47DQ39689968-1FCB6E86-A33C-4FB1-9209-332630EE6224Q39805145-7CE1F8D5-E678-4134-85F1-7099F0421BA5Q41769995-D326EE8F-F87B-409E-976B-C09D26E30A1AQ42878443-27034106-89F0-4108-AAF4-8598353F723AQ43184655-1F6C6834-EF09-46BE-B383-43D39C6D3429Q43552073-A134A742-D748-4A28-9853-448246ED9D63Q46237124-730D81F3-6859-4F9F-85C3-B2B410C96C80Q47834402-70DF6917-93EE-43CD-A85D-F08D9267397DQ49345557-1D4C91BE-E3D9-46C8-A267-62205E695B9CQ51081578-44D2B487-3F47-476A-A66D-FB491451AD47Q53417029-501D2681-C037-4DA2-999E-F7382FB2789F
P2860
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Optimizing drug development: s ...... potential--toward a consensus.
@ast
Optimizing drug development: s ...... potential--toward a consensus.
@en
Optimizing drug development: s ...... potential--toward a consensus.
@nl
type
label
Optimizing drug development: s ...... potential--toward a consensus.
@ast
Optimizing drug development: s ...... potential--toward a consensus.
@en
Optimizing drug development: s ...... potential--toward a consensus.
@nl
prefLabel
Optimizing drug development: s ...... potential--toward a consensus.
@ast
Optimizing drug development: s ...... potential--toward a consensus.
@en
Optimizing drug development: s ...... potential--toward a consensus.
@nl
P2093
P356
P1476
Optimizing drug development: s ...... potential--toward a consensus.
@en
P2093
P304
P356
10.1023/A:1010994022294
P577
2001-08-01T00:00:00Z